Biohaven Ltd. (BHVN)
NYSE • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Biohaven’s preliminary results for the third fiscal quarter of 2026 showed EPS of -$0.86 trailed the -$0.78 estimate by -$0.08, with the company reporting the quarter on October 29, 2026. The clinical-stage biotech posted a GAAP net loss of about $129.3 million, narrowing ~26% year over year from a loss of about $173.4 million, while EPS improved ~48% from -$1.64 a year ago. Operating income was a loss of roughly $126.4 million, reflecting the company’s ongoing spending tied to advancing drug candidates for nervous- and immune-system disorders through clinical trials rather than a mature commercial portfolio. Cash usage remained notable, with negative operating cash flow of about $106.9 million for the quarter. Looking ahead, next-period consensus calls for EPS of -$0.40 on revenue of $121.0 million.
About Biohaven Ltd.
Biohaven Ltd. is a clinical-stage Biotechnology company listed on the NYSE under BHVN. The company develops drug candidates for disorders affecting the nervous and immune systems, placing it in the healthcare sector, and it remains in the trial stage rather than operating as a mature commercial pharmaceutical business.
Today's Snapshot
BHVN closed 2.5% lower at 12.91, in line with a weaker sector. Biohaven highlighted a protein-degrader approach designed to remove disease-causing proteins.
Trading Volume
Below 10d avg (2.2M)
2M
vs S&P 500 Today
Underperforming Market
-2.23%
Updated: November 18, 2026 at 21:15 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$12.45 - $14.05Sell
- RSI (14)42.17Neutral
- Stochastic %K (14, 3, 3)5.49Buy
- MACD Level (12, 26)0.04Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.